Altimmune Inc (ALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2005 | |
| Cash Flows From Operating Activities | |
| Net Income | 277 |
| Accounts payable and accrued liabilities | 25 |
| Other Working Capital | 277 |
| Other Operating Activity | -25 |
| Operating Cash Flow | $554 |
| Cash Flows From Investing Activities | |
| Other Investing Activity | -68,636 |
| Investing Cash Flow | $-68,636 |
| Cash Flows From Financing Activities | |
| Change In Short Term Borrowing | 250 |
| Common Stock Issued | 75,225 |
| Other Financing Activity | -5,995 |
| Financing Cash Flow | $69,480 |
| End Cash Position | 1,398 |
| Net Cash Flow | $1,398 |
| Free Cash Flow | |
| Operating Cash Flow | 554 |
| Free Cash Flow | 554 |